<DOC>
	<DOC>NCT02287584</DOC>
	<brief_summary>The primary objective of the study is to evaluate the efficacy of DSP-5423P compared with placebo in patients with schizophrenia.</brief_summary>
	<brief_title>Confirmatory Study of DSP-5423P in Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Patients who have schizophrenia diagnosed by DSM5, diagnostic criteria Patients who are aged 18 years or older at informed consent Patient understands the objectives and procedures of the study and who provide written voluntarily consent to participate in the study, etc. Patients who fall under a contraindication listed in the blonanserin (LONASEN) package insert Patients with Parkinson disease Patients who previously received blonanserin, etc.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>